Clinical trials: ASCVD
ASCVD
Improving Implementation of Guideline-Recommended LDL-C Management in High-Risk Cardiovascular Patients
The goal of this observational study is to learn whether implementing evidence-based strategies in cardiology practices can improve guideline-recommended low-density lipoprotein cholesterol (LDL-C) management in adults at high…
- Trial name
- EMPOWER (NCT07883564)
- Where
- 5 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Cardiology Consultants of Philadelphia
sHTG, HTG With ASCVD (Diagnosed or at Increased Risk)
A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of FXR0906 in patients with severe hypertriglyceridemia or hypertriglyceridemia with atherosclerotic…
- Trial name
- NCT07889245
- Testing
- FXR0906 injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
Atherosclerotic Cardiovascular Disease, ASCVD
Managed Access Programs for TQJ230, Pelacarsen
The purpose of this registration is to list Managed Access Programs (MAPs) related to TQJ230, pelacarsen
- Trial name
- NCT07000695
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
ASCVD, LDL-C
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
The goal of this implementation trial is to learn if providing education to doctors and patients who have had a heart event works to prevent future heart problems. The main questions it aims to answer are: 1.
- Trial name
- T2T (NCT06471036)
- Testing
- Care Champion Intervention
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Vascular Inflammation, ASCVD
Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including…
- Conditions
- Vascular Inflammation, ASCVD, ASCVD Management
- Trial name
- TECTONIC (NCT06691217)
- Testing
- CANAKINUMAB (ILARIS®)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
ASCVD, ASCVD Management
Coronary Artery Calcium (CAC) Testing in Primary Care
The goal of this study is to improve how primary care providers identify and manage patients at risk for heart disease. One tool that can help with this is a coronary artery calcium (CAC) test, which looks for calcium buildup in…
- Conditions
- ASCVD, ASCVD Management, Coronary Artery Calcium, Hyperlipidemia
- Trial name
- NCT07868809
- Testing
- Our Practice Advisory (OPA)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Atherosclerotic Cardiovascular Disease (ASCVD)
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on…
- Trial name
- ADD-VANTAGE (NCT06813911)
- Testing
- Pelacarsen, Inclisiran
- Where
- 94 sites in United States, China and 9 more
- Volunteers
- 246 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension
Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management
The goal of this observational study is to evaluate the implementation of a structured, digital, nurse-led, remote monitoring care pathway for cardiovascular risk management (CVRM).
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension, Dyslipidemia
- Trial name
- TELE-CVRM (NCT07208331)
- Where
- Netherlands
- Volunteers
- 750 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- NCT06292013
- Testing
- Lepodisiran Sodium
- Where
- 928 sites in United States, Argentina and 26 more
- Volunteers
- 17,300 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD)
PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis
PCSK9 inhibitors, including evolocumab and alirocumab, are lipid-lowering therapies used in patients with hyperlipidemia and atherosclerotic cardiovascular disease.
- Trial name
- NCT07856264
- Volunteers
- 100 people
- Sponsor
- Fundación Santa Fe de Bogota
Hyperlipemia, Mixed, ASCVD
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management
A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values.
- Trial name
- LDL-ALERT (NCT05088759)
- Testing
- Alert
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- MOVE-Lp(a) (NCT07157774)
- Testing
- Muvalaplin
- Where
- 804 sites in United States, Argentina and 26 more
- Volunteers
- 10,450 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk
LDL Cholesterol Reduction Following Ezetimibe Initiation
This clinical trial will study why some people have a larger drop in low-density lipoprotein cholesterol (LDL-C), known as "bad cholesterol," after starting ezetimibe.
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk, LDL Cholesterol
- Trial name
- EZE-TRACK (NCT07839741)
- Testing
- Ezetimibe
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Universidade do Porto
Atherosclerotic Cardiovascular Disease (ASCVD), Erectile Dysfunction
Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction
This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction
- Trial name
- NCT07311330
- Testing
- YN001 20mg Dose + 5% glucose injection, 5% glucose injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Inno Medicine Co., Ltd.
Heart Failure, ASCVD
Serial Biomarker Testing and Cardiovascular Risk Stratification (ACHILLES)
The goal of this observational study is to learn how blood levels of biomarkers, e.g. hsCRP and Lp(a) - two markers linked to heart disease risk - change over time in patients who have had these levels tested more than once.
- Conditions
- Heart Failure, ASCVD, CKD
- Trial name
- ACHILLES (NCT07817576)
- Where
- Germany
- Volunteers
- 110,000 people
- Sponsor
- University Hospital Freiburg
ASCVD, Hyperlipidemia
Duke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Factors
This project is studying whether a team-based specialty clinic can help people with type 2 diabetes and heart disease better manage their blood pressure and cholesterol.
- Conditions
- ASCVD, Hyperlipidemia, Hypertension
- Trial name
- DUKE PREVENT (NCT07117695)
- Testing
- Referral to the Duke Cardiometabolic Prevention Clinic
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Duke University
Non-communicable Diseases (NCD), Neoplams
Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data
The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.
- Conditions
- Non-communicable Diseases (NCD), Neoplams, Cancer, Lung Cancer (NSCLC)
- Trial name
- H4H (NCT07743021)
- Where
- 33 sites in Hungary
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Center for Molecular Fingerprinting Research Nonprofit LLC
Testicular Cancer, Survivorship
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant
- Conditions
- Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease
- Trial name
- NCT05611307
- Testing
- Lipid profile, Coronary artery assessment, Hormone levels for hypogonadism
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Indiana University
Rheumatoid Arthritis (RA, Atherosclerotic Cardiovascular Disease (ASCVD)
The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study
Individuals with rheumatoid arthritis (RA) have up to 2x the risk of having a heart attack compared to someone without RA. The goal of this study is to identify biomarkers that can help us do a better job of identifying…
- Trial name
- CAT-RA (NCT07315997)
- Testing
- high sensitivity cardiac troponin
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Brigham and Women's Hospital